SWK Holdings Corp
NASDAQ:SWKH
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
15.16
18.29
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
SWK Holdings Corp
Revenue
SWK Holdings Corp
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
SWK Holdings Corp
NASDAQ:SWKH
|
Revenue
$53.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
14%
|
|
LM Funding America Inc
NASDAQ:LMFA
|
Revenue
$17.8m
|
CAGR 3-Years
6%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
||
A-Mark Precious Metals Inc
NASDAQ:AMRK
|
Revenue
$9.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
16%
|
CAGR 10-Years
5%
|
||
FlexShopper Inc
NASDAQ:FPAY
|
Revenue
$134.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
50%
|
||
California First Leasing Corp
OTC:CFNB
|
Revenue
$47.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
||
S
|
Standard Premium Finance Holdings Inc
OTC:SPFX
|
Revenue
$9.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
SWK Holdings Corp
Glance View
SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.
See Also
What is SWK Holdings Corp's Revenue?
Revenue
53.6m
USD
Based on the financial report for Sep 30, 2024, SWK Holdings Corp's Revenue amounts to 53.6m USD.
What is SWK Holdings Corp's Revenue growth rate?
Revenue CAGR 10Y
14%
Over the last year, the Revenue growth was 42%. The average annual Revenue growth rates for SWK Holdings Corp have been 1% over the past three years , 14% over the past five years , and 14% over the past ten years .